scholarly journals SARS-Cov-2 and COVID-19, Basic and Clinical Aspects of the Human Pandemic: A Review

2021 ◽  
Author(s):  
Mahdi Zavva ◽  
Hamid Emadi Kochak ◽  
Kamal Abdolmohammadi ◽  
Nesa Rashidi ◽  
Majid Mokhtari ◽  
...  
Keyword(s):  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Human Disease ◽  
Middle Eastern ◽  
Disease Status ◽  
Medical Community ◽  
Clinical Aspects ◽  
Multidimensional Approach ◽  
Laboratory Methods ◽  
Global Pandemic

In the last two decades, we have witnessed three major epidemics of the coronavirus human disease namely, severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome, and more recently an ongoing global pandemic of coronavirus disease 2019 (COVID-19). Iran, a country of nearly 84 million, in the Middle East, severely involved with the COVID-19 disease. A documented multidimensional approach to COVID-19 disease is therefore mandatory to provide a well-balanced platform for the concerned medical community in our county and beyond. In this review, we highlight the disease status in Iran and attempt to provide a multilateral view of the fundamental and clinical aspects of the disease including the clinical features of the confirmed cases, virology, pathogenesis, epidemiology, and laboratory methods needed for diagnosis.

scholarly journals COVID-19: the epidemiology and treatment

2020 ◽  
Vol 81 (10) ◽  
pp. 1-9
Author(s):  
Liujing Qu ◽  
Jinchun Li ◽  
Hao Ren
Keyword(s):  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Mortality Rates ◽  
Middle East Respiratory Syndrome ◽  
Cytokine Storm ◽  
Future Studies ◽  
Treatment And Prevention ◽  
Global Pandemic ◽  
Deadly Disease ◽  
Severe Lung

After initially emerging in late 2019, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly to cause a global pandemic. SARS-CoV-2 is a betacoronavirus that is closely related to severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, all of which can cause severe lung injury, respiratory distress and cytokine storm. While mortality rates associated with SARS-CoV-2 are lower than those associated with severe acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus, it is more contagious and spreads more rapidly than these other viruses. This article summarises the epidemiology and potential options for treating COVID-19 to give a foundation for future studies of the diagnosis, treatment and prevention of this deadly disease.

scholarly journals Investigation and Management of COVID-19

2021 ◽  
Author(s):  
Jovana Momic ◽  
Eric Di Gravio ◽  
Thulasie Manokaran ◽  
Ruchi Sharan ◽  
Meera Shah
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Diagnostic Tests ◽  
Clinical Presentation ◽  
Management Strategies ◽  
Hubei Province ◽  
Medical Community ◽  
Unknown Etiology ◽  
Infection Rates ◽  
Test And Treat ◽  
Global Pandemic

In December 2019, an outbreak of viral pneumonia of unknown etiology arose in Wuhan, Hubei Province, China. Eventually isolated and named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), this virus has caused a global pandemic of the pneumonia-like Coronavirus Disease (COVID-19). With global infection rates and deaths mounting, the medical community has been forced to recognize, test, and treat these patients within a rapidly evolving situation and a shortage of resources. In this article, we summarize the most recent data pertaining to the clinical presentation, diagnostic tests, imaging, and management strategies for COVID-19. This article concludes with a discussion of ongoing efforts to develop critically needed therapeutics and vaccines, which may subsequently shape our responses to future pandemics.

scholarly journals Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012

2012 ◽  
Vol 17 (40) ◽  
Author(s):  
A Bermingham ◽  
M A Chand ◽  
C S Brown ◽  
E Aarons ◽  
C Tong ◽  
...  
Keyword(s):  
United Kingdom ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Human Disease ◽  
Respiratory Illness ◽  
Gulf Region ◽  
The United Kingdom ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness

Coronaviruses have the potential to cause severe transmissible human disease, as demonstrated by the severe acute respiratory syndrome (SARS) outbreak of 2003. We describe here the clinical and virological features of a novel coronavirus infection causing severe respiratory illness in a patient transferred to London, United Kingdom, from the Gulf region of the Middle East.

scholarly journals SARS-CoV-2 and Covid-19 Immunopathogenesis

2020 ◽  
Author(s):  
Antonio Luiz Boechat ◽  
Beatriz Pessoa ◽  
Carlos Soares ◽  
Cecília Barroso ◽  
David Vila ◽  
...  
Keyword(s):  
Immune System ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Middle East Respiratory Syndrome ◽  
Clinical Progression ◽  
Immune Exhaustion ◽  
Global Pandemic ◽  
Pathologic Features ◽  
Cytokine Dysregulation ◽  
Disease Understanding

The coronavirus disease 2019 (COVID-19) is now a global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike other known coronaviruses, such as the Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 reveals new clinical, immunological, and pathologic features. The lymphocyte depletion, macrophage and neutrophil hyperactivation, cytokine dysregulation, thrombophilia, delayed antiviral response, and immune exhaustion are key immunological findings linked to the clinical progression of this disease. Understanding and identifying the underlying immunological basis of COVID-19 is crucial to designing effective therapies. Here, we provide an overview of immunopathogenesis driven by SARS-CoV-2 after its interactions with the immune system.

scholarly journals Brave new world an update on COVID-19 pandemic – A review

2020 ◽  
Author(s):  
K. Gadó ◽  
Gy. Domján ◽  
Z.Z. Nagy
Keyword(s):  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
20Th Century ◽  
21St Century ◽  
Human Disease ◽  
New World ◽  
Rna Viruses ◽  
Scientific Progress ◽  
History Of ◽  
Brave New World

AbstractEpidemics and pandemics have happened throughout the history of mankind. Before the end of the 20th century, scientific progress successfully eradicated several of the pathogens. While no one has to be afraid of smallpox anymore, there are some new pathogens that have never caused human disease before. Coronaviruses are a family of enveloped RNA viruses. In the 21st century, three of them have caused serious pandemics, including severe acute respiratory syndrome in 2002 and Middle East Respiratory Syndrome in 2012. In 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease-19 (COVID-19) pandemic, which has destroyed hundreds of thousands of lives and continues to rage.

scholarly journals Potential specific therapies in COVID-19

2020 ◽  
Vol 14 ◽  
pp. 175346662092685 ◽  
Author(s):  
Muhammad Hamdan Gul ◽  
Zin Mar Htun ◽  
Nauman Shaukat ◽  
Muhammad Imran ◽  
Ahmad Khan
Keyword(s):  
Clinical Trials ◽  
Severe Acute Respiratory Syndrome ◽  
Randomized Clinical Trials ◽  
Middle Eastern ◽  
The Other ◽  
Potential Treatment ◽  
Blood Products ◽  
Material Section ◽  
Global Pandemic ◽  
The World

COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section.

scholarly journals Understanding COVID-19: From Origin to Potential Therapeutics

2020 ◽  
Vol 17 (16) ◽  
pp. 5904
Author(s):  
Muhammad Moazzam ◽  
Muhammad Imran Sajid ◽  
Hamza Shahid ◽  
Jahanzaib Butt ◽  
Irfan Bashir ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Respiratory Infections ◽  
Middle Eastern ◽  
Clinical Manifestations ◽  
Current Status ◽  
The Public ◽  
Global Pandemic ◽  
First Case ◽  
Human Coronaviruses ◽  
Potential Therapeutics

Currently, a global pandemic era of public health concerns is going on with the Coronavirus Disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of COVID-19 was reported from Wuhan’s Huanan seafood market in China late December 2019. Bats, pangolins, and snakes have been nominated as salient carriers of the virus. Thanks to its high pathogenicity, it can cause severe respiratory infections. Fever, dry cough, sore throat, pneumonia, septic shock, and ground-glass opacities are the foremost clinical manifestations of COVID-19. Immunocompromised patients are at high risk for COVID-19 infection and may lead to death. Scientist and government agencies around the globe are putting forward their best efforts and resources for the effective treatment of human coronavirus infections; however, neither vaccines nor antiviral drugs are available for the treatment of human coronaviruses (HCoV) infections such as SARS (severe acute respiratory syndrome), MERS (Middle Eastern respiratory syndrome), and COVID-19. Since the outbreak, a plethora of research and review articles have been published. Moreover, the mass media has bombarded the public with conflicting opinions about the pandemic. There is a dire need for accurate and reliable information concerning this pandemic. In this review, we have compiled the up to date information about the origins, evolution, epidemiology, and pathogenesis of this disease. Moreover, very few reports have addressed the clinical features and current status of treatment for COVID-19; we have adequately addressed these topics in detail in this review. Finally, a detailed account of clinical trials of vaccines and other therapeutics currently in progress has been delineated.

scholarly journals The epidemiology and therapeutic options for the COVID-19

2020 ◽  
Vol 3 (2) ◽  
pp. 71-84 ◽  
Author(s):  
Jingwei Li ◽  
Jun Shao ◽  
Chengdi Wang ◽  
Weimin Li
Keyword(s):  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Clinical Features ◽  
Large Scale ◽  
First Century ◽  
Therapeutic Options ◽  
Global Pandemic ◽  
Number Of Patients ◽  
The World ◽  
Great Harm

Abstract An outbreak of coronavirus disease 2019 (COVID-19), a disease caused by a novel pneumonia virus, has affected over 200 countries and regions worldwide. With the increasing number of patients and deaths, WHO have declared it as a global pandemic currently, indicating a third large-scale epidemic coronavirus has appeared since the emergence of severe acute respiratory syndrome coronavirus (SARS) and Middle-East respiratory syndrome (MERS) in the twenty-first century. Considering the great harm it has caused, researchers throughout the world have been chasing to exploit the pathophysiology, characteristics, and potential remedies for COVID-19 to better battle the outbreak. Therefore, the current study revisits advances of the virology, epidemiology, clinical features, therapeutic options, and prevention of COVID-19. The features of asymptomatic carriers are also been explored.

scholarly journals Evaluation of SSYA10-001 as a Replication Inhibitor of Severe Acute Respiratory Syndrome, Mouse Hepatitis, and Middle East Respiratory Syndrome Coronaviruses

2014 ◽  
Vol 58 (8) ◽  
pp. 4894-4898 ◽  
Author(s):  
Adeyemi O. Adedeji ◽  
Kamalendra Singh ◽  
Ademola Kassim ◽  
Christopher M. Coleman ◽  
Ruth Elliott ◽  
...  
Keyword(s):  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Broad Spectrum ◽  
Hepatitis Virus ◽  
Middle Eastern ◽  
Mouse Hepatitis Virus ◽  
Binding Pocket ◽  
Middle East Respiratory Syndrome ◽  
Replication Inhibitor

ABSTRACTWe have previously shown that SSYA10-001 blocks severe acute respiratory syndrome coronavirus (SARS-CoV) replication by inhibiting SARS-CoV helicase (nsp13). Here, we show that SSYA10-001 also inhibits replication of two other coronaviruses, mouse hepatitis virus (MHV) and Middle Eastern respiratory syndrome coronavirus (MERS-CoV). A putative binding pocket for SSYA10-001 was identified and shown to be similar in SARS-CoV, MERS-CoV, and MHV helicases. These studies show that it is possible to target multiple coronaviruses through broad-spectrum inhibitors.

scholarly journals Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions

2020 ◽  
Author(s):  
A.C. Fears ◽  
W.B. Klimstra ◽  
P. Duprex ◽  
A. Hartman ◽  
S.C. Weaver ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Human Population ◽  
Middle Eastern ◽  
Etiological Agent ◽  
Short Term ◽  
Zoonotic Pathogen ◽  
Global Pandemic ◽  
A Current

The emergent coronavirus, designated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a zoonotic pathogen that has demonstrated remarkable transmissibility in the human population and is the etiological agent of a current global pandemic called COVID-191. We measured the dynamic (short-term) aerosol efficiencies of SARS-CoV-2 and compared the efficiencies with two other emerging coronaviruses, SARS-CoV (emerged in 2002) and Middle Eastern respiratory syndrome CoV (MERS-CoV; emerged starting in 2012). We also quantified the long-term persistence of SARS-CoV-2 and its ability to maintain infectivity when suspended in aerosols for up to 16 hours.

Sign in / Sign up

Export Citation Format

Share Document